CMI-392 |
Catalog No.GC33905 |
Le CMI-392 est un double inhibiteur de la 5-lipoxygénèse et un antagoniste des récepteurs du facteur d'activation plaquettaire (PAF) avec des IC50 de 100 et 10 nM, respectivement.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 205654-37-1
Sample solution is provided at 25 µL, 10mM.
CMI-392 is a dual 5-lipoxygenese inhibitor and platelet-activating factor (PAF) receptor antagonist with IC50s of 100 and 10 nM, respectively.
Topical treatment of CMI-392 in the acute and chronic TPA models result in a significant decrease of ear weight, inflammatory cell infiltration, and histological examination. The ED50 for PAF-induced mouse hemoconcentration and arachidonic acid-induced mouse ear edema are 2.2 and 1.8 mg/kg, respectively[1].
[1]. Cai X, et al. (+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist. J Med Chem. 1998 May 21;41(11):1970-9.
Average Rating: 5
(Based on Reviews and 29 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *